IBI310
Current Locations:Home > PRODUCTS > IBI310
IBI310—重组人CTLA-4融合蛋白注射液
         IBI310通过阻断CTLA-4的免疫效应,刺激免疫细胞大量增殖,从而诱导或增强抗肿瘤免疫反应。与PD-1联合治疗,有望用于肺癌、黑色素瘤,肾癌等难治性肿瘤。
Copyright © 2011- Innovent Biologics, Inc.
Powered by RuiXi